We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Laboratory-Developed Tests Market Driven by Cancer Treatment

By LabMedica International staff writers
Posted on 28 Nov 2017
Print article
The global market for laboratory-developed tests (LDTs) is estimated to be worth USD 13.2 billion and will grow by nearly 10% annually, driven mainly by oncology tests which will grow 60% faster than other types of LDTs. These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

The trend of tests produced in a lab or sold commercially as a test service product is growing. Laboratories continue to develop and use LDTs due to the commercial unavailability of clinical needs for LDTs for assays. LDTs were historically low-volume, simple and well characterized tests for low-risk diagnostic applications. Of late, complex LDTs based on technologies such as next generation sequencing have become available for new applications, including oncology.

Currently, oncology is a large segment of the clinical LDT market, in terms of revenue. Several tests have been developed for diagnosis, predicting prognosis, providing information to aid in determining the best treatment for an individual patient, and for monitoring treatment – all aspects of personalized medicine in cancer. Another significant application and market segment is predicting the risk of hereditary cancer. Additionally, new tests have been introduced for screening apparently healthy individuals for cancer, and the cancer screening market is growing at a very rapid pace.

"Cancer treatment is driving this test market, and LDTs are more important, and profitable in cancer testing than any other area," said Bruce Carlson, Publisher of Kalorama Information.

However, the increasing visibility, complexity, and risk of LDT for certain applications, such as oncology have attracted calls for increased regulation of the market. Any sudden changes to the market, such as an abrupt requirement for all LDTs to meet stringent regulations or be removed from the market, could potentially result in several essential clinical tests becoming unavailable. This has raised significant concerns over the potential future changes in the regulation of LDTs, including FDA regulation of LDTs.

"This is a very crowded market. Not all companies will succeed," said Lucy Sannes of Sannes & Associates, who authored the report.

Related Links:
Kalorama Information

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.